Shire, Rani to develop oral factor VIII therapy
Shire and Rani Therapeutics have signed a deal to work on developing an orally-delivered therapy for patients with hemophilia A.
Read More
Tag: Rani
- Lario Therapeutics awarded $2.4m to advance calcium channel platform
- Mikrobiomik secures approval for gut‑microbiota therapy for C difficile infection
- Exdensur approved in EU for severe asthma and CRSwNP
- Axol Bioscience acquires Newcells Biotech ophthalmology unit
- Nuclera and leadXpro partner to accelerate structure‑based drug design
